Profile data is unavailable for this security.
About the company
Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)453.30m
- Net income in HKD-1.14bn
- Incorporated2017
- Employees520.00
- LocationEverest Medicines Ltd16/F., CITIC Pacific Plaza,1168 West Nanjing Road, JingAn DistrictSHANGHAI 200041ChinaCHN
- Websitehttps://www.everestmedicines.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Shineway Pharmaceutical Group Ltd | 4.55bn | 1.20bn | 7.28bn | 3.23k | 5.56 | 0.9159 | 5.27 | 1.60 | 1.58 | 1.58 | 6.03 | 9.61 | 0.4476 | 1.28 | 5.26 | 1,325,273.00 | 11.76 | 8.03 | 15.47 | 9.77 | 75.21 | 74.55 | 26.27 | 17.87 | 3.14 | -- | 0.0457 | 36.29 | 14.32 | 11.94 | 34.14 | 13.89 | 0.6396 | 12.88 |
| Consun Pharmaceutical Group Ltd | 2.97bn | 905.85m | 7.34bn | 3.18k | 7.70 | 1.82 | 7.40 | 2.47 | 1.12 | 1.12 | 3.68 | 4.75 | 0.5209 | 2.00 | 12.89 | 948,638.10 | 15.97 | 12.04 | 23.24 | 19.25 | 74.22 | 74.55 | 30.66 | 24.89 | 2.80 | -- | 0.1144 | 40.84 | 10.71 | 7.03 | 14.88 | 11.01 | -22.93 | 18.43 |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 6.00bn | 1.78bn | 7.85bn | 4.89k | 4.40 | 0.8364 | 3.79 | 1.31 | 2.03 | 2.03 | 6.82 | 10.66 | 0.4272 | 2.50 | 3.74 | 1,299,337.00 | 11.69 | 8.03 | 17.27 | 11.81 | 78.90 | 79.97 | 27.37 | 20.80 | 1.93 | 50.79 | 0.2126 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| AIM Vaccine Co Ltd | 1.28bn | -1.29bn | 9.43bn | 1.56k | -- | 2.49 | -- | 7.36 | -1.06 | -1.06 | 1.06 | 3.13 | 0.1462 | 0.6325 | 1.10 | 789,712.40 | -22.69 | -- | -37.16 | -- | 72.34 | -- | -155.22 | -- | 0.6836 | -6.61 | 0.3437 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
| Beijing Biostar Pharmaceuticals Co Ltd | -100.00bn | -100.00bn | 10.68bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 103.03 | -- | -18.15 | -- | -- | -- |
| Luye Pharma Group Ltd | 6.84bn | 834.43m | 10.68bn | 5.23k | 12.80 | 0.7577 | 6.36 | 1.56 | 0.2218 | 0.2218 | 1.82 | 3.75 | 0.236 | 2.44 | 3.02 | 1,297,484.00 | 3.11 | 2.80 | 5.47 | 4.45 | 68.73 | 70.53 | 13.18 | 10.39 | 1.20 | 3.14 | 0.4103 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| Shanghai Henlius Biotech Inc | 6.11bn | 749.82m | 11.39bn | 3.55k | 15.22 | 4.08 | 9.90 | 1.86 | 1.38 | 1.38 | 11.19 | 5.14 | 0.5764 | 1.90 | 6.82 | 1,679,642.00 | 7.07 | -8.59 | 14.25 | -14.14 | 73.23 | 71.77 | 12.27 | -27.37 | 0.329 | 7.60 | 0.6113 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| SSY Group Ltd | 6.47bn | 1.37bn | 11.42bn | 5.80k | 8.40 | 1.58 | 6.24 | 1.77 | 0.4593 | 0.4593 | 2.18 | 2.44 | 0.5418 | 2.75 | 3.07 | 1,155,141.00 | 11.54 | 10.51 | 14.88 | 14.03 | 54.39 | 58.72 | 21.30 | 18.62 | 2.06 | 28.65 | 0.323 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| Everest Medicines Ltd | 453.30m | -1.14bn | 11.80bn | 520.00 | -- | 2.43 | -- | 26.03 | -3.54 | -3.54 | 1.41 | 14.89 | 0.0756 | 5.23 | 3.22 | 1,049,317.00 | -19.03 | -30.52 | -20.21 | -33.14 | 75.74 | -- | -251.64 | -5,745.25 | 4.62 | -- | 0.1119 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| China Traditional Chinese Med Hldg CoLtd | 18.63bn | 993.61m | 12.04bn | 17.72k | 12.11 | 0.52 | 5.31 | 0.6459 | 0.1973 | 0.1973 | 3.70 | 4.60 | 0.453 | 1.54 | 1.82 | 1,076,853.00 | 2.62 | 4.60 | 4.01 | 7.07 | 49.86 | 57.07 | 5.77 | 9.77 | 1.51 | 7.39 | 0.1808 | 17.35 | 26.69 | 9.99 | 68.11 | -2.24 | -12.75 | -- |
| 3SBio Inc | 9.12bn | 1.80bn | 14.04bn | 5.61k | 7.95 | 0.9011 | 6.30 | 1.54 | 0.7374 | 0.7374 | 3.74 | 6.50 | 0.3575 | 1.52 | 6.87 | 1,685,595.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 141.55 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 16.65bn | 10.78k | 6.81 | 1.06 | 5.79 | 1.57 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 4.54 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
Data as of Nov 13 2024. Currency figures normalised to Everest Medicines Ltd's reporting currency: Hong Kong Dollar HKD
9.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janchor Partners Ltd.as of 30 Sep 2023 | 15.88m | 4.88% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 3.75m | 1.15% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 3.11m | 0.96% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 2.38m | 0.73% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 2.19m | 0.67% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 1.77m | 0.55% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 1.21m | 0.37% |
| Ping An Fund Management Co., Ltd.as of 30 Jun 2024 | 1.01m | 0.31% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 486.00k | 0.15% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 424.50k | 0.13% |
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
